Table 1.
Summary of Responders
| Patient | Age | Race/Gender | Smoking status | Histology | HER2 alteration | Testing Method | Other alterations | Systemic Therapy*# | Best Responseˆ | PFS |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| #1 | 62 | C/F | <10 pack year | Adeno | Exon 20 ins (A775_G77 6 insSVMA) | Foundation One NGS | After recurrence: | |||
| carbo/gem/bev, then gem/bev maintenance X6 mo docetaxel X1 mo | SD PD |
6 mo | ||||||||
| Pem X2.5 mo | PD | |||||||||
| Irinotecan X2 mo | PD | |||||||||
| Tras/vinorelbine X6 mo | PR (−32%) | 6 mo | ||||||||
|
| ||||||||||
| #2 | 67 | A/F | Never | Adeno | A775_G77 6 insYVMA | STAMP NGS | RB1 R320L, ASTN1 R214W, IFLTD1 L71P, DDX1 V429I, FAM5C D431V | Carbo/pem, then pem maintenance X9 mo | PR | 9 mo |
| Tras/docetaxel X 8 mo | PR (−33%) | 8 mo | ||||||||
| Afatinib X 1 mo | SD (+2%) | 1 mo | ||||||||
|
| ||||||||||
| #3 | 61 | C/F | 10 pack year | Carcinoma | A775_G77 6 insYVMA | STAMP NGS | PIK3CA R88Q | Carbo/docetaxel/bev + investigational anti-Met therapy X15 mo | PR | 1 mo |
| Tras/vinorelbine X7 mo | SD (+2%) | 5 mo | ||||||||
| Tras/docetaxel X5mo | SD (+9%) | 5 mo | ||||||||
|
| ||||||||||
| #4 | 36 | A/F | Never | Adeno | Exon 20 ins (exact sequence unknown) | PCR amplification | HER2 amplification | Carbo/pem/bev, then pem/bev maintenance X 4.5mo | PR | 4.5 mo |
| Erlotinib X 1 mo | PD | |||||||||
| Afatinib X 6.5 mo | PR (−43%) | 5 mo | ||||||||
| Tras/vinorelbine X 6 mo | PR (−35%) | 6 mo | ||||||||
| Tras/docetaxel X4 mo | SD (−3%) | 4 mo | ||||||||
| Ado-trastuzumab X2 mo | PD | |||||||||
| Nivolumab X 1mo etirinotecan pegol (clinical trial) X 2mo | PD PD |
|||||||||
| Afatinib/bev X 3 months | Mixed response, with SD (−20%) in lung and PD in liver | n/a | ||||||||
*
HER2 targeted therapies in bold
#
number indicates number of cycles unless otherwise specified
ˆ
as determined by RECIST v1.1 criteria
C: Caucasian
A: Asian
M: male
F: female
Adeno: adenocarcinoma
mo: month
PFS: progression free survival
NGS: next generation sequencing
STAMP: Stanford solid tumor actionable mutation panel
SD: stable disease
PD: progressive disease
PR: partial response
Tras: trastuzumab
Gem: gemcitabine
Bev: bevacizumab
Carbo: carboplatin
Pem: pemetrexed